Product
Sacituzumab Govitecan-hziy
Aliases
GS-0132, IMMU-132, Sacituzumab Govitecan-hziy (SG)
3 clinical trials
4 indications
Indication
Lung CancerIndication
Solid TumorIndication
AdultIndication
NSCLCClinical trial
An Open-label, Multicenter, Phase 2 Study of Sacituzumab Govitecan Combinations in First-line Treatment of Patients With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) Without Actionable Genomic AlterationsStatus: Active (not recruiting), Estimated PCD: 2024-08-01
Clinical trial
Open-Label, Global, Multicenter, Randomized, Phase 3 Study of Sacituzumab Govitecan Versus Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Progression on or After Platinum-Based Chemotherapy and Anti-PD-1/PD-L1 ImmunotherapyStatus: Active (not recruiting), Estimated PCD: 2023-11-29
Clinical trial
A Phase I/II, First-In-Human, Multi-Part, Open-Label, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of DF1001 in Patients With Locally Advanced or Metastatic Solid Tumors, and Expansion in Selected IndicationsStatus: Recruiting, Estimated PCD: 2026-10-01